Management Committee

Pascal PRIGENT holds a Master of Business Administration from INSEAD (1995) and is a graduate of Reims Business School (1989). Prior to joining GENFIT as our Executive Vice President, Marketing and Development, he was Vice President Marketing-U.S. Vaccines for GlaxoSmithKline USA from April 2014 to November 2017. Prior to this, he was Vice President and General Manager of GlaxoSmithKline Romania from January 2011 to March 2014. He also served in various roles at Eli Lilly and its affiliates from 1996 through January 2011. Pascal is GENFIT’s CEO, effective on September 16, 2019. He has chaired the Management Committee since taking office.

Sakina SAYAH-JEANNE joined GENFIT on April 3rd, 2023 as Executive Vice-President Research & Translational Science, member of the Management Committee. She was appointed Chief Scientific Officer of the company on September 30, 2025, following the retirement of Dean Hum, Chief Scientific Officer of GENFIT since 2000. Sakina has more 20 years pharmaceutical industry experience, including 7 years at GENFIT. Sakina obtained her PhD in Molecular and Cellular Biology in 1998, specializing in Neuro-Immunology, at the University of Rouen (Role of the complement in central nervous system pathologies with an inflammatory component). In 1999, Sakina joined Innothera, a French pharmaceutical group, as Project Leader, Pharmacology (Neurogenic pain). In 2002, Sakina joined GABA Laboratoire, as Scientific Attaché (oral and dental care). Sakina joined GENFIT in 2003 as a Project Leader, Preclinical. She then became Director of Therapeutic Target Research in 2005 (Cardiometabolic diseases, Alzheimer’s disease). In 2011, Sakina joined DaVolterra as the Manager of the Preclinical Research, to define and manage the nonclinical strategy for mechanistic and proof-of-concept studies for the product under development (Gut microbiome protection for the prevention of infectious diseases). In 2015, she was appointed Senior Director, Translational and Transversal R&D, where she was in charge of producing decision support for clinical development of the product, addressing questions around dose regimen and safe use for the different indications and populations, developing argumentations and defending Sponsor’s position statements with regulatory authorities (Gut microbiome protection for (i) prevention of infectious diseases, (ii) efficacy of anti-cancer treatments).

Pascal Caisey joined GENFIT in September 2019 as Executive Vice President of Commercial Development, becoming Chief Commercial Officer in January 2021. In March 2022, he was appointed Deputy Chief Executive Officer and Chief Operating Officer of the Group. Pascal has extensive operational pharmaceutical business experience, having notably held positions of increasing responsibility at GSK, BMS, Pfizer, and most recently Boehringer Ingelheim. Mr. Caisey is a registered nurse and holds an MBA from HEC.

Thomas BAETZ graduated from ESCP-Europe in 1996 and ENSAE, where he obtained his Master's degree in Finance and Actuarial Science in 1998. His professional career includes various experiences in France, the United States, and Asia, notably when he joined Crédit Lyonnais in Singapore, Andersen Business Consulting in France, and then the listed company CEGEDIM (Euronext: CGM). He headed up Management Control there, then moved to New York to lead the financial integration of the Dendrite group. He then became Senior Vice President – Corporate Development, with particular responsibility for mergers and acquisitions. Thomas joined GENFIT on April 1, 2021, as Chief Financial Officer, after working for seven years in Hong Kong and Paris as CFO & Head of Asia-Pacific for medtech company Impeto Medical, then as Director of Healthcare for Dragon Financial Partners, specializing in fundraising and licensing agreements for European biotech companies.

John BROZEK holds three master’s degrees respectively in Cell and Molecular Biology from Lille University, Bioinformatics from Paris 7 University and Information Technology from Amiens University. He started his career in 2001 as Bioinformatician with IT-omics, a startup specializing in Information Systems design and data mining for biotech companies. In 2005, he joined GENFIT where he progressively took the lead of In Silico activities providing support in bioinformatics, biostatistics and Information Systems design. Since 2016, in addition to managing the In Silico activities, he leads the IT Department where he has been focusing on a global Information System renewal project while continuing to develop data related project (data science and business intelligence).

Emilie DESODT joined GENFIT in January 2018 as Human Resources Director. Emilie has been working in Human Resources for more than 20 years in various operational and strategic positions. Prior to joining GENFIT, Emilie was in charge of HR activities, first at regional level (Americas & Middle East) then at global level at the Lesaffre Group. She has also held various HR roles of increasing responsibilities within General Electric. Emilie holds a bachelor’s degree in computer sciences (MIAGE) and a master’s degree in HR Development.

Laurent LANNOO graduated from the University of Lille law school with a degree in Business Law (DESS Juriste d’Entreprise). He began his professional career at M&M, a consulting firm, in 1994, becoming partner in 1996. One of the consulting projects led him to join Eurasanté, the public agency for the economic development of healthcare activities in the Nord – Pas de Calais region of France in 1995, where he was in charge of finance and administration from 1996 to 2005. Thereafter, he was the Corporate Secretary of the Cœur et Artères foundation and chairman of its executive board from 2005 to 2008. In 2008, he joined GENFIT as Corporate Secretary and Director of Legal Affairs.

Stefanie MAGNER joined GENFIT in 2016 as Deputy Director of Legal Affairs. Prior to joining GENFIT, she spent nearly 10 years at the Paris offices of the global U.S. law firm, Jones Day advising issuers, many in the biotech space, and banks on a variety of corporate, cross-border securities and M&A transactions, including several U.S. IPOs. She is admitted to practice law in New York and is a former member of the Paris Bar. She graduated from the University of Pennsylvania with a Bachelor of Arts in International Relations and French, as well as an international diploma from Sciences-Po Paris. She received her U.S. law degree from Washington College of Law at the American University in Washington D.C. and holds a Masters of Business Litigation from the Université de Paris X – Nanterre. Stefanie holds the position of Chief Compliance Officer, EVP International Legal Affairs since 2021.

Jean-Christophe MARCOUX is an engineer graduated from INSA Lyon (France), and also holds a degree in Strategic Management and Economic Intelligence from the Ecole de Guerre Economique in Paris (France). Part of his education was completed at the University of Leeds (United Kingdom). He led for nearly 15 years international programs in various industrial sectors, in Europe and Asia, interacting with American teams and clients. In 2012, he joined the consulting firm now known as IQVIA, the global leader in services and technologies for healthcare stakeholders. There, he led projects of various kinds covering longitudinal patient studies, forecasting, targeting, profiling, prospective analyses, digital health and innovation. He joined GENFIT at the end of 2015 as VP Corporate Affairs and played a transversal role on tactical, strategic and operational matters. He was later appointed Chief Strategy Officer, then Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG.

Tom HUIJBERS joined GENFIT in 2023 as Executive Vice-President Regulatory, member of the Management Committee. Tom has more than 20 years of experience in the pharmaceutical industry. In 1999, he graduated with a Master of Science in Medicinal Chemistry and Molecular Pharmacology, from the University of Groningen (Netherlands). The same year, he joined the Janssen Research Foundation (Belgium) as Associate Manager Regulatory Affairs.In 2004, he joined Grünenthal GmbH based in Germany, as Regulatory Affairs Manager. As of 2006, he became Senior Regulatory Affairs Manager before holding the positions of Associate Director Global Regulatory Affairs, then Senior Director Global Regulatory Affairs between 2009 and 2018.In 2018, Tom became Vice President, Head Development Strategy & Intelligence in Grünenthal’s Innovation Unit Devices and Technologies.Before joining GENFIT, Tom had worked since 2020 at Pinney Associates (USA) and Harm Reduction Therapeutics (USA), as an Independant Regulatory Affairs Consultant.

With over 20 years of experience in the pharmaceutical and biotechnology industry, Dr. MOTLAGH brings extensive expertise in drug development strategy across multiple therapeutic areas. His leadership will be instrumental in shaping GENFIT’s clinical development programs and advancing its pipeline. Prior to joining GENFIT, Dr. MOTLAGH served as CMO at Egle Therapeutics, a company focused on therapies targeting regulatory T cells for oncology and autoimmune diseases. He also held the role of CMO at Mablink Biosciences, a biotechnology company specializing in next-generation antibody-drug conjugates (ADCs). Earlier in his career, Dr. MOTLAGH contributed to the success of several large pharmaceutical organizations, playing a key role in advancing compounds from early phase clinical development up to commercialization.

*Member of Executive Committee